A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of MT-3921 in Subjects With Acute Traumatic Cervical Spinal Cord Injury
Latest Information Update: 09 Oct 2024
Price :
$35 *
At a glance
- Drugs Unasnemab (Primary)
- Indications Spinal cord injuries
- Focus Proof of concept; Therapeutic Use
- Sponsors Mitsubishi Tanabe Pharma America
- 30 Jul 2024 Planned End Date changed from 1 Feb 2025 to 1 Apr 2025.
- 30 Jul 2024 Planned primary completion date changed from 1 Nov 2024 to 1 Jan 2025.
- 30 Jul 2024 Status changed from recruiting to active, no longer recruiting.